Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia

Tian-shu Yu,1 Hao-yi Wang,1 Ya-jing Zhao,1 Ya-fei Yu,1 Yu Hou,1 Shuang Liu,2 Pan-pan Han,1 Xiao-fei Ni,1 Xue-bin Ji,1 Jun Peng,1,3 Xin-guang Liu,1 and Ming Hou1,3,4

1Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University; 2Department of Hematology, Taian Central Hospital, Taian, China; 3Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University; and 4Leading Research Group of Scientific Innovation, Department of Science and Technology of Shandong Province, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

Primary immune thrombocytopenia (ITP) is an autoantibody-mediated hemorrhagic disorder in which B cells play an essential role. Previous studies have focused on peripheral blood (PB), but B cells in bone marrow (BM) have not been well characterized. We aimed to explore the profile of B-cell subsets and their cytokine environments in the BM of patients with ITP to further clarify the pathogenesis of the disease. B-cell subpopulations and their cytokine/chemokine receptors were detected by using flow cytometry. Plasma concentrations of cytokines/chemokines were measured by using enzyme-linked immunosorbent assay. Messenger RNA levels of B cell–related transcription factors were determined by using quantitative polymerase chain reaction. Regulatory B cell (Breg) function was assessed by quantifying their inhibitory effects on monocytes and T cells in vitro. Decreased proportions of total B cells, naive B cells, and defective Bregs were observed in patients with ITP compared with healthy controls (HCs), whereas an elevated frequency of long-lived plasma cells was found in BM of autoantibody-positive patients. No statistical difference was observed in plasmablasts or in short-lived plasma cells between patients with ITP and HCs. The immunosuppressive capacity of BM Bregs from patients with ITP was considerably weaker than HCs. An in vivo study using an active ITP murine model revealed that Breg transfusion could significantly alleviate thrombocytopenia. Moreover, overactivation of CXCL13-CXCR5 and BAFF/APRIL systems were found in ITP patient BM. Taken together, B-cell subsets in BM were skewed toward a proinflammatory profile in patients with ITP, suggesting the involvement of dysregulated BM B cells in the development of the disease.

Introduction

Primary immune thrombocytopenia (ITP) is a common autoimmune hemorrhagic disorder characterized by decreased platelet counts and increased risk of bleeding.1 Abnormalities of humoral and cellular immunity are involved in the pathogenesis of ITP.2,3 Aside from autoantibody-mediated platelet phagocytosis, direct lysis of platelets by cytotoxic T lymphocytes, and impaired thrombopoiesis,4,5 disrupted T-cell subsets such as follicular T helper (Th) cell elevation, enhanced Th1 polarization, and Th17/regulatory T-cell (Treg) dysregulation also hold key positions in the development of ITP.6 Diagnosis of ITP relies on exclusion of other causes of thrombocytopenia,7 and not all patients respond to existing treatments.8 Generally, ITP is a
in the BM of patients with ITP.14,15 Function of BM mesenchymal stem cells (BM-MSCs) from patients with ITP has also been observed in the peripheral blood (PB) of patients with ITP.12,13 Bone marrow (BM) is the site of hematopoiesis and is known for its ability to regenerate hematopoietic cells. Unbalanced naive and memory B cells, as well as decreased regulatory B cells (Bregs), have been found in the peripheral blood of patients with ITP.16,17 However, few studies have profiled BM B cells in ITP.

In the present study, different B-cell subsets and B cell–related cytokines/chemokines and their receptors were measured in the PB and BM of patients with ITP and healthy controls (HCs). We found that total B cells, naive B cells, and Bregs were significantly decreased in ITP patient BM, whereas an elevated frequency of long-lived plasma cells (LLPCs) was found in autoantibody-positive patients. We also observed that the immunosuppressive capacity of BM Bregs from patients with ITP was compromised, and transfusion of BM-derived Bregs into an active ITP murine model could ameliorate thrombocytopenia. Moreover, enhanced interaction of CXCL13 with CXCR5 and overactivation of the B cell–activating factor/a proliferation-inducing ligand (BAFF/APRIL) system were found in ITP. These abnormalities provide new insights into the immune dysregulation in ITP.

Materials and methods

Patients and HCs

A total of 25 newly diagnosed treatment-naive patients with ITP (9 male subjects and 16 female subjects; 19-71 years of age; median age, 45 years) were enrolled between February 2018 and December 2019 at the Department of Hematology, Qilu Hospital, Shandong University, Jinan, China. All patients met the diagnostic criteria,18 and their BM was routinely examined according to Chinese ITP guidelines.19

Patients’ platelet counts ranged from 1 to 38 × 10^9/L, with a median count of 15 × 10^9/L. The main features of the enrolled patients are shown in Table 1. The HC group consisted of 20 healthy volunteers (10 male subjects and 10 female subjects; 18-52 years of age; median age, 40 years) who were related donors for hematopoietic stem cell transplantation. Several examinations, such as BM morphology, complete blood count, and kidney and liver function, were conducted before donation. Platelet counts of HCs ranged from 127 to 294 × 10^9/L, with a median count of 222 × 10^9/L.7

BM aspirates of the posterior superior iliac spine were obtained under aseptic conditions by experienced physicians. BM aspirate smears were examined simultaneously. To minimize PB dilution, ~1 mL of BM blood was first aspirated for B-cell subset quantification, and

| Table 1. Clinical characteristics of enrolled patients with ITP |
|---|
| Patient no. | Sex/age (y) | PLT (<10^9/L) | Symptoms | Anti-GP autoantibody |
| 1 | Female/21 | 29 | PT + GH | (-) |
| 2 | Female/45 | 38 | GH + ME | GPIb/IIa(+) GPIb/IX(+) |
| 3 | Female/27 | 5 | ME | GPIb/IIa(+) GPIb/IX(+) |
| 4 | Female/34 | 1 | EC + GH | (-) |
| 5 | Female/60 | 11 | (-) | GPIb/IIa(+) GPIb/IX(+) |
| 6 | Female/19 | 32 | EP + GH | (-) |
| 7 | Male/33 | 6 | PT + GIH | (-) |
| 8 | Female/68 | 15 | PT + EC | GPIb/IIa(+) GPIb/IX(+) |
| 9 | Male/58 | 8 | EC + GH | (-) |
| 10 | Female/67 | 15 | PT + GH | (-) |
| 11 | Female/42 | 11 | (-) | GPIb/IIa(+) |
| 12 | Female/43 | 20 | PT + GH + CH | (-) |
| 13 | Male/55 | 33 | (-) | (-) |
| 14 | Female/57 | 15 | EC | GPIb/IX(+) |
| 15 | Male/23 | 35 | (-) | GPIb/IX(+) |
| 16 | Female/53 | 5 | EC | (-) |
| 17 | Male/52 | 13 | (-) | GPIb/IX(+) |
| 18 | Female/67 | 10 | PT + GH + ME | (-) |
| 19 | Male/64 | 13 | GH | GPIb/IX(+) |
| 20 | Male/58 | 35 | (-) | GPIb/IX(+) |
| 21 | Female/31 | 1 | PT + ME | (-) |
| 22 | Male/32 | 11 | PT | GPIb/IIa(+) |
| 23 | Male/40 | 19 | (-) | (-) |
| 24 | Female/31 | 24 | (-) | GPIb/IIa(+) |
| 25 | Female/71 | 21 | CH | GPIb/IIa(+) |

(-), no bleeding symptom; CH, cerebral hemorrhage; EC, ecchymoses; EP, epistaxis; GH, gingival hemorrhage; GIH, gastrointestinal hemorrhage; GP, glycoprotein; ME, menorrhagia; PT, petechiae.

Table 2. Primers and conditions for quantitative polymerase chain reaction

| Gene | Sequence (5’-3’) | Annealing T (C) | Product (bp) |
|---|---|---|---|
| GAPDH | F: GCACCGGCTCAAGGCTGAGAAC | 60 | 138 |
| CXCR5 | F: ATCCGGCGTGAGCGCTGACC | 60 | 84 |
| BACE-R | F: CTGTCGCAATCTCTCAGTGAT | 60 | 70 |
| BCMA | F: CATGTCAGAATCCAGGCTGTC | 60 | 120 |
| TACI | F: AGCAAGGCAAGTTCACTATGACCCTC | 60 | 157 |
| XBP1 | F: CCTGGTCGTCAGGAAAGGAGG | 60 | 145 |
| PAx5 | F: GCCATAGCTCAGTCTCACTCAGAAGAG | 60 | 123 |
| IFR4 | F: GACGCAATTAGGAGGCTCACA | 60 | 205 |
| PRDM1 | F: CCCCTCGAGAAAGAAGAATG | 60 | 241 |

heterogeneous disease, the pathogenesis of which requires further exploration to improve diagnosis and management.

B cells are a subtype of lymphocytes that produce antibodies and generate immunologic memory. Over the last decades, the significance of B cells in autoimmunity has become increasingly recognized. On the one hand, B cells play pathogenic roles by producing autoantibodies and presenting autoantigens; on the other hand, B cells implement anti-inflammatory effects through their immunosuppressive subpopulations.9,10 ITP is a classical model of an organ-specific autoimmune disorder in which autoreactive B cells take center stage in disease development.11 Unbalanced naive and memory B cells, as well as decreased regulatory B cells (Bregs), have been found in the peripheral blood (PB) of patients with ITP.12,13 Bone marrow (BM) is the site for differentiation of various hematopoietic cells, but its immune microenvironment remains unclear. Imbalance of T-cell subsets has been observed in the BM of patients with ITP.14,15 Function of BM mesenchymal stem cells (BM-MSCs) from patients with ITP has also been reported to be defective.16,17 However, few studies have profiled BM B cells in ITP.
Figure 1. Total B cells, immature B cells, naive B cells, and memory B cells of patients with ITP and HCs. (A) Elimination of adherent cells and fragments, and gate settings for lymphocytes from BM and PB. (B, C) patients with ITP had fewer CD19⁺ B cells in BM (7.81 ± 0.84% vs 15.26 ± 1.84%; P < .001) but more in PB (6.94 ± 0.63% vs 4.83 ± 0.41%; P = .013) compared with HCs. (D, E) No statistical difference was found in the proportion of CD19⁺ B cells between BM and PB in patients with ITP (P = .893), whereas the proportion of BM CD19⁺ B cells was significantly higher than its PB counterparts in HCs (15.26 ± 1.84% vs 4.83 ± 0.41%; P = .002). (F, G) No difference was found in CD19⁺CD127⁻ immature B-cell compartments in BM CD19⁺ cells between patients with ITP and HCs (4.91 ± 0.94% vs 4.01 ± 0.58%; P = .504), whereas a lower frequency of CD19⁺CD127⁻ B cells in lymphocytes was observed in patients with ITP (0.22 ± 0.07% vs 0.53 ± 0.12%; P = .029). (H) Density plots of CD27 and CD38 double staining from CD19⁺ cells in flow cytometry. CD19⁺CD27⁻ cells (Q1 + Q3) were naive B cells, and CD19⁺CD27⁻CD38⁻ cells (Q4) were memory B cells. (I, J)
then 4 to 5 mL was further acquired for cell isolation and culture in the functional assays.

This study was approved by the Medical Ethical Committee of Qilu Hospital, Shandong University. Informed consent was obtained from each participant before being included in the study in accordance with the Declaration of Helsinki.

**Supplemental methods**

The reagents and protocols about flow cytometry, quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, modified monoclonal antibody-specific immobilization of platelet antigen, and in vitro and in vivo functional assays of Bregs are described in detail in the supplemental Methods. The primer sequences are listed in Table 2.

**Statistical analysis**

Results are presented as mean ± standard error of mean, or median and range, depending on the type of data distribution. Normally distributed data are described with mean ± standard error of the mean (line with error bars), and data that were not normally distributed are presented with median (one line) and range. All tests were performed by using SPSS 22.0 (IBM SPSS Statistics, IBM Corporation). Pictures were drawn by using GraphPad Prism 8.3 (GraphPad Software). Statistical significance between patients with ITP and HCs was determined by an independent-sample Student t test or Mann-Whitney U test. Comparisons between PB and BM from the same case were made by using the paired samples Student t test or Wilcoxon matched-pairs signed-rank test. P values <.05 were considered statistically significant.

**Results**

**Decreased percentage of total B cells and disrupted balance of naive/memory B cells in the BM of patients with ITP**

After removing adherent cells and fragments, forward scatter and side scatter were used to define the lymphocyte population (Figure 1A). As shown in Figure 1B, the frequency of CD19+ B cells in BM from patients with ITP was significantly lower than that from HCs. By contrast, the number of B cells in PB from patients with ITP was remarkably higher compared with HCs (Figure 1C). Therefore, there might be an abnormal chemotaxis of B cells between BM and PB in patients with ITP. Notably, we found no difference in B cells between BM and PB in the ITP group (Figure 1D), whereas the percentage of B cells in lymphocytes in BM was significantly higher than that in PB from HCs (Figure 1E). The percentage of BM CD19+CD127− immature B-cell compartments among CD19+ cells was similar between patients with ITP and HCs (Figure 1F), but within total lymphocytes, the percentage of immature B-cell compartments was significantly reduced compared with HCs (Figure 1G).

The percentages of CD19+CD27− naive B cells and CD19+CD27+CD38−low memory B cells in CD19+ B cells were also analyzed (Figure 1H). Lower BM naive B cells in patients with ITP were found compared with HCs (Figure 1I), but no statistical difference in PB naive B cells was found between patients with ITP and HCs (Figure 1J). The frequencies of BM memory B cells in CD19+ cells from patients with ITP were higher compared with HCs (Figure 1K); however, higher naive B cells were observed in the BM than in the PB from HCs (Figure 1L). No statistical significance in memory B cells was found between the BM and PB in patients with ITP (Figure 1O), whereas fewer memory B cells were observed in BM B cells than that in PB B cells from HCs (Figure 1P). Percentages of different B-cell subpopulations within lymphocytes were also analyzed, and the trends are shown in Table 3.

**Plasmablasts and plasma cells in BM and PB**

We identified CD19+CD27−CD38−CD138+ Ki67+ as plasmablasts and CD19+CD27−CD38−CD138+ Ki67− as short-lived plasma cells (SLPCs) (Figure 2A). No statistical difference was found in the percentage of BM or PB plasmablasts among CD19+ cells between patients with ITP and HCs (Figure 2B-E). Moreover, there was no significant difference in the proportion of BM or PB SLPCs in B cells between patients with ITP and HCs (Figure 2F-G). Higher frequency of SLPCs existed in BM B cells, from both patients with ITP and HCs, than in PB (Figure 2H). Percentages of plasmablasts and SLPCs in lymphocytes were also calculated, and no difference was observed (Table 3). The proportions of plasmablasts and SLPCs were also analyzed between patients with positive anticytoplasmic autoantibodies and HCs, but there was still no statistical difference (data not shown).

CD19+CD38−CD138− LLPCs have been reported to be involved in the occurrence of several autoimmune diseases. We analyzed the proportion of LLPCs in BM mononuclear cells and found no statistical difference (Figure 2J-K). Interestingly, the percentage of LLPCs in BM from autoantibody-positive patients was significantly higher than that from HCs and autoantibody-negative patients (Figure 2K).

By contrast, we found no difference between autoantibody-negative patients and HCs.

**Decreased BM Bregs and their effector cytokines in patients with ITP**

Compared with HCs, patients with ITP had a significantly smaller percentage of CD19+CD27+CD38+ Bregs in B cells both in

---

**Figure 1** (continued) percentage of naive B cells was significantly lower in BM B cells from patients with ITP compared with HCs (84.04 ± 3.04% vs 77.33 ± 2.33%; *P = .011), whereas no statistical difference was found in PB naive B cells between patients with ITP and HCs (median [range], 69.36% [47.66–93.53%] vs 67.69% [49.45–85.50%]; *P = .817). (K, L) No statistical difference was observed in naive B cells between BM and PB from patients with ITP (median [range], 69.82% [47.66–93.53%] vs 69.39% [47.66–93.53%]; *P = .731), whereas more naive B cells existed in BM B cells than in PB from HCs (78.10 ± 2.38% vs 64.53 ± 3.24%; *P < .001). (M, N) The frequency of memory B cells was higher in BM B cells of patients with ITP than that of HCs (26.23 ± 3.20% vs 12.61 ± 2.57%; *P = .002), but no difference was observed in PB memory B cells between patients with ITP and HCs (25.17 ± 2.98% vs 22.84 ± 4.42%; *P = .654). (O, P) No statistical difference was found in percentage of memory B cells in CD19+ cells between BM and PB in patients with ITP (26.23 ± 3.20% vs 25.17 ± 2.98%; *P = .813). HCs had remarkably decreased frequency of memory B cells in BM compared with PB (12.61 ± 2.57% vs 22.84 ± 4.42%; *P = .021). *P < .05; **P < .01; ***P < .001. APC, allophycocyanin; FITC, fluorescein isothiocyanate; FSC-A, forward scatter pulse area; SSC-A, side scatter pulse area.
There was no remarkable difference in percentage of SLPCs in CD19+ patients with ITP and HCs. Moreover, no significantly higher than that from HCs (median [range], 0.27% [0.13%-1.38%] vs 0.10% [0.02%-0.42%]; P = .273). The proportion of BM LLPCs from autoantibody-positive patients was significantly higher than that from HCs (median [range], 0.27% [0.13%-1.38%] vs 0.10% [0.02%-0.42%]; P = .021) and autoantibody-negative patients (median [range], 0.27% [0.13%-1.38%] vs 0.08% [0.01%-0.15%]; P < .001), whereas no significant difference was found between autoantibody-negative patients and HCs (P = .485). *P < .05; **P < .01; ***P < .001.

CD19+ cells in ITP patients

Table 3. Comparison of percentages of B-cell subsets in lymphocytes between patients with ITP and HCs

| B-cell subset       | Patients with ITP | HCs       | P   | Patients with ITP | HCs       | P   |
|---------------------|-------------------|-----------|-----|-------------------|-----------|-----|
| Immature B          | 0.22 ± 0.07       | 0.53 ± 0.12 | .029|                   |           |     |
| Naive B             | 4.66 ± 0.66       | 12.52 ± 1.75 | <.001| 4.95 ± 0.61       | 3.16 ± 0.38 | .273|
| Memory B            | 1.52 ± 0.25       | 1.51 ± 0.24 | .992| 1.28 ± 0.22       | 1.14 ± 0.27 | .693|
| Plasmablast         | 0.06 ± 0.03       | 0.07 ± 0.03 | .782| 0.06 ± 0.01       | 0.05 ± 0.02 | .617|
| SLPC                | 0.79 ± 0.26       | 1.03 ± 0.26 | .543| 0.018 ± 0.005     | 0.016 ± 0.008 | .843|
| Breg                | 0.58 ± 0.15       | 2.84 ± 0.34 | <.001| 0.05 ± 0.01       | 0.18 ± 0.04 | .004|

BM, bone marrow; HCs, healthy controls; ITP, immune thrombocytopenia; PB, peripheral blood; SLPC, short-lived plasma cell.
Figure 3. Decreased number and impaired ability of BM Bregs to secrete inhibitory cytokines in patients with ITP. (A) Representative density plots of BM and PB CD19⁺CD24⁺CD38⁺ Bregs in patients with ITP and HCs. (B, C) The percentages of BM (median [range], 5.50% [0.03%-16.77%] vs 18.67% [4.58%-36.72%]; P < .001) and PB (median [range], 0.31% [0.02%-2.27%] vs 3.05% [0.77%-15.19%]; P < .001) Bregs in CD19⁺ cells were significantly lower in patients with ITP compared with their respective counterparts in HCs. (D, E) Both patients with ITP and HCs had more Bregs in BM B cells than in PB B cells (patients with ITP: median [range], 5.50% [0.03%-16.77%] vs 0.31% [0.02%-2.27%]; P < .001; HCs: median [range], 18.67% [4.58%-36.72%] vs 3.05% [0.77%-15.19%]; P = .001). (F, G) Quantification of IL-10⁺ or TGF-β⁺ B cells in BM CD19⁺ cells from patients with ITP and HCs, respectively. (H, I) BM B cells from patients with ITP produced less IL-10 (2.35 ± 0.51% vs 7.15 ± 0.86%; P < .001) and TGF-β (median [range], 1.32% [0.39%-4.11%] vs 4.10% [1.34%-9.11%]; P = .028) compared with HCs after stimulation with CPG-ODN. *P < .05, **P < .01, ***P < .001. APC, allophycocyanin; CPG-ODN, CPG oligonucleotide; FITC, fluorescein isothiocyanate; PE, phycoerythrin; SSC, side scatter.
Figure 4.
BM (Figure 3A-B) and PB (Figure 3A, C). The tendency of Breg frequency between BM and PB in patients with ITP and HCs was similar, which showed considerably elevated BM Bregs compared with their PB counterparts (Figure 3D-E). The percentages of BM and PB Bregs within lymphocytes were also decreased remarkably compared with HCs (Table 3). It is still controversial whether Foxp3-expressing B cells exist. Our results showed that CD19+Foxp3+ cells were detectable at a low level in a small proportion of patients and HCs, but they could not be found in most samples (data not shown).

Interleukin-10 (IL-10) and transforming growth factor β (TGF-β) are important effector cytokines through which Bregs exert immunosuppressive functions. We stimulated the in vitro cultured BM-derived mononuclear cells (BMMNCs) with Toll-like receptor 9 agonists and measured expression of intracellular IL-10 and TGF-β in B cells (Figure 3F-G). The percentage of BM IL-10+ B cells (Figure 3H) and TGF-β+B cells (Figure 3I) in patients with ITP were both significantly lower than that in HCs.

**Functional evaluation of BM Bregs in vitro and in vivo**

Because bona fide Bregs were difficult to obtain due to the lack of specific markers, we tested the in vitro suppressive ability of BM B cells activated with CD40 and Toll-like receptor 9 agonists on monocyte’s tumor necrosis factor-α (TNF-α) secretion as a reflection of the function of Bregs. As shown in Figure 4A to C, the frequency of TNF-α+ monocytes cocultured with activated BM B cells was significantly lower than that cultured alone, both in patients with ITP and in HCs. Notably, the inhibition of monocyte’s TNF-α secretion by BM B cells in patients with ITP was greatly reduced compared with that in HCs (Figure 4D).

We further examined the inhibitory capacity of BM B cells on CD4+ T cells. BM B cells in patients with ITP (Figure 4E-F) and HCs (Figure 4E, G) both inhibited interferon-γ (IFN-γ) secretion by CD4+ T cells, but statistical significance was not reached in the ITP group. BM B cells from patients with ITP had less inhibition compared with those from HCs (Figure 4H). With regard to Treg induction, BM B cells from patients with ITP and HCs both enhanced the percentage of Tregs in CD4+ T cells (Figure 4K). Notably, Treg promotion by BM B cells from patients with ITP was significantly lower than those from HCs (Figure 4L).

In addition, the therapeutic effect of BM-derived Bregs was evaluated in a previously described active ITP murine model. As shown in Figure 4M, ITP mice treated with BM-derived Bregs from immunized CD61-KO mice had significantly higher platelet counts than control ITP mice on days 14, 21, and 28 after splenocyte transfusion.

**Abnormal B-lineage transcription factors in patients with ITP**

Transcription factors involved in differentiation and development of B cells were determined by using quantitative polymerase chain reaction. As shown in Figure 5A, the level of paired box 5 (Pax5) messenger RNA (mRNA) in BMMNCs from patients with ITP was remarkably lower than that from HCs, whereas no significant difference was observed in X-box–binding protein 1 (XBP-1) or interferon regulatory factor 4 (IRF4). In PBMCs, the Pax5 mRNA level from patients with ITP was more than sixfold lower than that from HCs (Figure 5B). The mRNA levels of XBP1 and IRF4 were also significantly reduced in PBMCs from patients with ITP compared with HCs. No significant difference was observed in positive regulatory domain I–binding factor 1 between patients with ITP and HCs (data not shown).

**Aberrant B cell–related cytokines/chemokines in patients with ITP**

CXCL13, BAFF, and APRIL are the 3 cytokines/chemokines closely related to B-cell maturation and survival. The levels of BM and PB CXCL13 from patients with ITP were significantly higher than their counterparts from HCs (Figure 5C-D). In addition, BAFF concentrations in BM and PB from patients with ITP were also significantly higher than those from HCs (Figure 5G-H). However, increased APRIL in patients with ITP was only found in the BM but not the PB compared with HCs (Figure 5K-L).

Levels of these 3 cytokines were also compared between BM and PB. In the ITP group, we found that the level of APRIL in BM was significantly higher than in PB (Figure 5M), whereas no statistical difference in APRIL level between BM and PB in HCs was observed (Figure 5N). We found no statistical difference in CXCL13 or BAFF levels between BM and PB in patients with ITP or HCs (5E, F, I, and J). Those results indicate that B cells in patients with ITP have abnormal developmental and chemotactic environments, which might contribute to their dysregulation.

**Figure 4. Compromised immunoregulatory capacity of BM Bregs from patients with ITP.** (A) Quantification of CD14+ TNF-α+ monocytes cultured alone or with activated BM B cells that contained Bregs from patients with ITP and HCs, respectively. (B, C) Percentage of TNF-α+ monocytes cocultured with BM B cells was significantly lower than that cultured alone, both in patients with ITP (21.24 ± 4.90% vs 36.61 ± 7.82%; P = .001) and in HCs (15.70 ± 5.44% vs 41.52 ± 11.90%; P = .001). (D) BM B cells from patients with ITP exhibited decreased capacity to suppress monocyte TNF-α production compared with HCs (39.95 ± 5.45% vs 61.55 ± 6.89%; P = .029). The percentage of inhibition was calculated as [1 – (percentage of TNF-α+ monocytes cocultured with B cells/percentage of TNF-α+ monocytes cultured alone)] × 100%. (E) IFN-γ secreted by CD4+ T cells cultured alone or with BM B cells from patients with ITP and HCs, respectively. (F, G) BM B cells from the ITP (16.31 ± 4.89% vs 14.48 ± 4.09%; P = .283) and HC (26.22 ± 3.47% vs 15.85 ± 2.31%; P < .001) groups both inhibited IFN-γ secretion by CD4+ T cells, but statistical significance was not reached in the ITP group. (H) Inhibition of CD4+IFN-γ+ T cells by BM B cells from patients with ITP was weaker than that from HCs (median [range], 22.78% [6.84%-35.80%] vs 42.10% [30.16%-48.72%]; P = .009). Percentage of inhibition was calculated as [1 – (percentage of CD3+ IFN-γ+ T cells cocultured with B cells/percentage of CD3+ IFN-γ+ T cells cultured alone)] × 100%. (I) CD4+ T cells cultured alone or with BM B cells for 72 hours, and frequencies of CD4+CD25+ Foxp3+ Tregs were determined by using flow cytometry. (J, K) BM B cells from patients with ITP and HCs both enhanced the percentage of Tregs in CD4+ T cells (patients with ITP, 4.04 ± 1.31% vs 15.09 ± 3.40%; P = .007; HCs, 1.32 ± 0.38% vs 21.93 ± 1.89% [P < .001]). (L) BM B cells from patients with ITP had weaker ability to promote Treg differentiation compared with HCs (median [range], 3.74 [1.58-14.55] vs 20.70 [8.82-25.82]; P = .009). Promotion of Tregs was calculated as Tregs % cocultured with B cells/Tregs % cultured alone. (M) Platelet counts of active ITP mice transfused with BM Bregs from immunized CD61-KO mice were higher than that of control group mice on days 14, 21, and 28 after splenocyte transfusion. *P < .05; **P < .01; ***P < .001. APC, allophycocyanin; PE, phycoerythrin; SSC, side scatter.
Figure 5.
Abnormal expression of chemokine/cytokine receptors on B cells in patients with ITP

CXCL13 and CXCR5 are a chemokine and receptor pair that is crucial for B-cell trafficking, activation, and germinal center formation. BAFF/APRIL and their receptors compose an important system indispensable for B-cell differentiation, maturation, immunoglobulin class switching, and antibody production. BAFF binds to 3 different receptors: BAFF receptor (BAFF-R), B-cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI), while APRIL only binds to BCMA and TACI. Surface levels of CXCR5, BAFFR, BCMA, and TACI on B cells were determined by using flow cytometry. CXCR5 on BM B cells from patients with ITP was significantly higher than that from HCs (Figure 6A-B). A significant increase in B-cell CXCR5 was also observed in PB from patients with ITP compared with HCs (Figure 6C). Moreover, surface levels of CXCR5 on B cells in BM were much lower than their matched counterparts in PB from both patients with ITP (Figure 6D) and HCs (Figure 6E). Similarly, BAFF-R levels were also elevated in BM from patients with ITP compared with HCs (Figure 6F-H). In addition, BM BAFF-R levels from both patients with ITP and HCs were considerably lower compared with their PB counterparts (Figure 6I-J). The levels of BCMA on B cells were generally low; we only found a statistical increase in BM BCMA level from patients with ITP compared with HCs (Figure 6K-N). As for the difference between BM and PB, a significantly decreased level of BCMA on B cells was detected in BM compared with PB from HCs (Figure 6O). No statistical difference was found in B-cell TACI in BM or PB between patients with ITP and HCs (Figure 6P-S).

In line with the changing trends in surface receptors at the protein level, mRNA levels of B-cell CXCR5 and BAFF-R from patients with ITP were significantly higher than those in HCs, both in BM and PB (Figure 7A-D). Moreover, BCMA and TACI in BM B cells from patients with ITP were also remarkably elevated compared with HCs (Figure 7E, G). We found no statistical difference in BCMA or TACI in PB B cells between patients with ITP and HCs (Figure 7F, H).

Discussion

Abnormalities of peripheral B cells in ITP have been well characterized, but little is known about the profile of BM B cells of the disease. In the present study, we showed for the first time that levels of total B cells, naive B cells, and Bregs were significantly lower in the BM of patients with ITP compared with those from patients with ITP. However, the CXCL13-CXCR5 axis and BAFF/APRIL system were also found to be abnormally expressed and distributed in patients with ITP. Those results suggest disrupted immune tolerance of B cells and aberrant BM chemotactic microenvironments in patients with ITP.

Although there is undoubtedly an imbalance in B-cell subsets in patients with ITP, the specific changes of each subpopulation remain unclarified. Fang et al.27 and Giordano et al.28 reported some controversies about B-cell subsets in pediatric patients with ITP. With regard to adult patients, Lyu et al.13 reported increased total B cells and memory B cells, with reduced naive B cells in the PB of active patients with ITP. In the present study, significantly reduced total B cells, immature B-cell compartments, and naive B cells were discovered in the BM of patients with ITP, whereas the proportions of memory B cells, plasma blasts, and SLPCs showed no statistical difference between patients with ITP and HCs. B cells are derived from pluri-potent hematopoietic stem cells through a series of developmental stages and selection steps in the BM. After successful generation of the functional B-cell receptor, immature B cells develop into naive B cells and are released into PB. Receptor editing, clonal deletion, and clonal anergy are the main mechanisms for the maintenance of early B-cell tolerance, and defects in receptor editing would lead to increased clonal deletion.29

Our unpublished data have shown insufficient receptor editing in naive B cells of patients with ITP, which might elevate the elimination of immature B-cell compartments by clonal deletion. Therefore, the reduction in BM immature B-cell compartments and naive B cells could be largely attributed to the decreased production of these early B-cell subsets.

Li et al.30 showed that BM CD38<sup>hi</sup>CD133<sup>+</sup> cells from patients with chronic ITP were higher than those from HCs. Here, we found that frequency of LLPCs from autoantibody-positive patients was considerably higher than that from HCs and autoantibody-negative patients. Recently, Shrestha et al.31 showed that the detection rate of autoantibodies in BM was higher than in PB. Therefore, autoantibodies might be at higher titers in BM than in PB, and BM could be a site where autoantibodies were produced. Because LLPCs predominantly reside in BM, the higher detection rate of autoantibodies in BM might be due to the in situ production of autoantibodies by LLPCs. LLPCs could be produced not only by migration of plasma blasts to BM but originating from reactivation of memory B cells in situ,32 which occurs both in spleen and BM.33 Consequently, BM memory B cells and plasma blasts could be a potential source of autoreactive B cells. Platelets are mainly produced by megakaryocytes in the BM, and in patients with ITP was greatly reduced. Moreover, the CXCL13-CXCR5 axis and BAFF/APRIL system were also found to be abnormally expressed and distributed in patients with ITP. Those results suggest disrupted immune tolerance of B cells and aberrant BM chemotactic microenvironments in patients with ITP.

Figure 5. Aberrant expression of B-lineage transcription factors and abnormal B cell–related cytokines/chemokines in patients with ITP. (A) Patients with ITP had decreased mRNA levels of Pax5 in BMMNCs compared with HCs (0.0049 ± 0.0002 vs 0.0100 ± 0.0017; P < .022). No statistical difference was found in mRNA expression of XBP1 or IRF4 in BMMNCs between patients with ITP and HCs (all P > .05). (B) mRNA levels of Pax5 (0.0017 ± 0.0005 vs 0.0108 ± 0.0016; P < .001), XBP1 (0.0201 ± 0.0033 ± 0.0631 ± 0.0093; P < .001), and IRF4 (0.0037 ± 0.0007 vs 0.0182 ± 0.0037; P < .001) in PBMCs from patients with ITP were much lower compared with HCs. (C, D) Plasma concentrations of BM CXCL13 in patients with ITP were much higher than in HCs (BM: median [range], 94.08 pg/mL [34.46-423.50 pg/mL] vs 55.33 pg/mL [13.31-97.54 pg/mL], P < .003; PB: median [range], 83.21 pg/mL [53.12-291.96 pg/mL] vs 59.27 pg/mL [27.73-116.58 pg/mL], P < .029). (E, F) No difference was found in plasma CXCL13 between BM and PB from the ITP or HC group (all P > .05). (G, H) Plasma levels of BAFF in BM and PB of patients with ITP were higher compared with that in HCs (BM: median [range], 1338.0 pg/mL [989.6-3419.6 pg/mL] vs 1123.0 pg/mL [459.6-1499.6 pg/mL], P < .011; PB: median [range], 1388.0 pg/mL [993.6-3451.6 pg/mL] vs 1022.0 pg/mL [559.6-1255.6 pg/mL], P < .001). (I, J) No divergence was found in BAFF between BM and PB from patients with ITP or HCs (all P > .05). (K, L) Higher plasma concentration of APRIL was observed in BM from patients with ITP than in HCs (median [range], 3.79 ng/mL [1.12-9.34 ng/mL] vs 2.34 ng/mL [1.56-3.79 ng/mL], P < .005), whereas no difference was found in PB between patients with ITP and HCs (median [range], 1.49 ng/mL [0.47-4.53 ng/mL] vs 1.96 ng/mL [1.42-4.36 ng/mL], P = .230). (M, N) Plasma APRIL was lower in PB than in BM in patients with ITP (median [range], 3.79 ng/mL [1.12-9.34 ng/mL] vs 1.49 ng/mL [0.47-4.53 ng/mL], P < .001; no such tendency was found in HCs (median [range], 2.52 ng/mL [1.35-3.18 ng/mL] vs 1.96 ng/mL [1.42-4.53 ng/mL], P = .770). *P < .05; **P < .01; ***P < .001.
autoantibodies could bind newly released platelets or megakaryocytes, leading to increased platelet destruction and decreased platelet production. Furthermore, it has been reported that excessive LLPCs could inhibit the production of pro- and pre-B cells, which might account for the decrease in total B cells in the BM of autoantibody-positive patients.

Pax5 is expressed throughout the whole life of B cells and controls the commitment of B-lineage cells. Downregulation of Pax5 and upregulation of XBP-1 and IRF4 are involved in the process of antibody-secreting cell differentiation. The mRNA levels of these 3 transcription factors were remarkably reduced in PBMCs of patients with ITP; among them, Pax5 decreased the most, suggesting that defects in...
B-cell generation and a tendency toward differentiation into antibody-secreting cells might be involved in the pathophysiology of ITP. As for the discrepancy of those transcription factors between BM and PB, the varied expression of those transcription factors in different B-cell developmental stages could be the main reason.

In addition to antibody secretion and antigen presentation, B cells contain a regulatory subset, known as Bregs, which are capable of suppressing immune responses. In PB, a reduced number of Bregs have been reported, and the abnormalities could be corrected by dexamethasone or thrombopoietic agents. In our study, we found a higher concentration of plasma BAFF in both BM and PB from patients with ITP, whereas no statistical difference was found in PB B cells between patients with ITP and HCs. (G) TACI mRNA levels of BM B cells in patients with ITP were also higher than those in PB from patients with ITP and HCs. (H) TACI mRNA levels of BM B cells in patients with ITP were also higher than those in HCs (0.064 ± 0.018 vs 0.016 ± 0.004; P < .001), whereas no statistical difference was found in PB B cells between patients with ITP and HCs.

Figure 7. mRNA levels of CXCR5, BAFF-R, BCMA, and TACI of B cells. (A, B) The mRNA level of B-cell CXCR5 from patients with ITP was also higher than that from HCs, both in BM (0.070 ± 0.021 vs 0.016 ± 0.007; P < .004) and PB (median [range], 0.071 [0.015 to 0.338] vs 0.035 [0.017-0.086]; P < .017). (C, D) Increased mRNA levels of BAFF-R in BM (0.066 ± 0.020 vs 0.011 ± 0.003; P < .024) and PB (median [range], 0.090 [0.010-0.443] vs 0.030 [0.012-0.115]; P < .023) B cells from patients with ITP was found compared with HCs. (E, F) Elevated mRNA levels of BCMA were observed in BM B cells of patients with ITP compared with HCs (0.049 ± 0.011 vs 0.012 ± 0.002; P < .011), whereas no statistical difference was found in PB B cells between patients with ITP and HCs. (G) TACI mRNA levels of BM B cells in patients with ITP were also higher than those in HCs (0.064 ± 0.018 vs 0.016 ± 0.004; P < .001).
with ITP had elevated levels of BAFF in BM and PB and an increased concentration of APRIL in BM. In contrast to previous reports, increased BAFF-R on B cells in both BM and PB, and elevated BCMA on B cells in BM, from patients with ITP was found in our study. In the last decade, the efficacy and safety of the BAFF/APRIL antagonists belimumab and atacicept in the treatment of autoimmune diseases have been gradually verified. In view of the hyperfunction of the BAFF/APRIL system in patients with ITP, these monoclonal antibodies might be effective in refractory cases.

In conclusion, BM B cells in patients with ITP were in a state of immune deviation characterized by decreased total B cells, naive B cells, and defective Bregs. The aberrant profile of BM B cells coincided with elevated levels of B cell–related cytokines/chemokines and abnormal distribution of their receptors. Therefore, the abnormalities of BM B cells and their chemotactic environments might provide new therapeutic targets for the management of ITP.

Acknowledgments
The authors thank Alexandra H. Marshall (Marshall Medical Communications) for providing editorial assistance during preparation of the manuscript.

This work was supported by the Cultivation Project of Qilu Sanitation and Health Leading Talents (2019), the National Natural Science Foundation of China (No. 81570103), and the Clinical Science and Technology Innovation Program of Jinan Science and Technology Project (No. 201704085).

Authorship
Contribution: Material preparation, data collection, and analysis were performed by T.Y., H.W., Y.Z. P.H., Y.Y., Y.H., S.L., X.N., X.J., J.P., and M.H.; the first draft of the manuscript was written by T.Y. and X.L.; and all authors commented on previous versions of the manuscript; All authors contributed to the study conception and design, and all authors read and approved the final manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: Y.Y., 0000-0003-4516-4714; Y.H., 0000-0002-1403-1882.

Correspondence: Xin-guang Liu, Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; e-mail: Liuxingrant@163.com; and Yu Hou, Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; e-mail: houyu2009@sina.com.

References

1. Abadi U, Yarchovsky-Dolberg O, Ellis MH. Immune thrombocytopenia: recent progress in pathophysiology and treatment [in French]. Clin Appl Thromb Hemost. 2015;21(5):397-404.
2. Audia S, Mahèvas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620-632.
3. Audia S, Mahèvas M, Bonnotte B. Immune thrombocytopenia: from pathogenesis to treatment [in French]. Rev Med Interne. 2021;42(1):16-24.
4. Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015;6(1):7737.
5. Olsson B, Andersson PO, Jernås M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-1124.
6. Kostic M, Zivkovic N, Cvetanovic A, Marjanović-G. CD4+ T cell phenotypes in the pathogenesis of immune thrombocytopenia. Cell Immunol. 2020;351:104096.
7. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
8. Cooper N. State of the art—how I manage immune thrombocytopenia. Br J Haematol. 2017;177(1):39-54.
9. Hofmann K, Claude AK, Manz RA. Targeting B cells and plasma cells in autoimmune diseases. Front Immunol. 2018;9:835.
10. Lampropoulou V, Calderon-Gomez E, Roch T, et al. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol Rev. 2010;233(1):146-161.
11. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16.
12. Li X, Zhong H, Bao W, et al. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood. 2012;120(16):3318-3325.
13. Lyu M, Hao Y, Li Y, et al. Upregulation of CD72 expression on CD19+CD27+ memory B cells by CD40L in primary immune thrombocytopenia. Br J Haematol. 2017;178(2):308-318.
14. Song Y, Wang YT, Huang XJ, Kong Y. Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia. Ann Hematol. 2016;95(6):959-965.
15. Wang Q, Li J, Yu TS, et al. Disrupted balance of CD4+ T-cell subsets in bone marrow of patients with primary immune thrombocytopenia. Int J Biol Sci. 2019;15(13):2798-2814.
16. Pérez-Simón JA, Tabera Š, Sarasquete ME, et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy. 2009;11(6):698-705.
17. Zhang D, Li H, Ma L, et al. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity. 2014;47(8):519-529.
18. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv.* 2019;3(22):3780-3817.

19. Liu XG, Bai XC, Chen FP, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. *Int J Hematol.* 2018;107(6):615-623.

20. Halliley JL, Tipton CM, Liesveld J, et al. Long-lived plasma cells are contained within the CD19(−)CD38(hi)CD138(+) subset in human bone marrow. *Immunity.* 2015;43(1):132-145.

21. Mahévas M, Michel M, Weill JC, Reynaud CA. Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. *Front Immunol.* 2013;4:494.

22. Winter O, Dame C, Jundt F, Hiepe F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. *J Immunol.* 2012;189(11):5105-5111.

23. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. *Blood.* 2010;115(6):1247-1253.

24. Guo L, Kapur A, Aslam R, et al. CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia. *Blood.* 2016;127(6):735-738.

25. Kazanian MG, Durando M, Cooke M. Cxcl13 and its receptor cxcr5 in cancer: inflammation, immune response, and beyond. *Front Endocrinol (Lausanne).* 2019;10:471.

26. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. *Cytokine Growth Factor Rev.* 2013;24(3):203-215.

27. Fang J, Lin L, Lin D, et al. The imbalance between regulatory memory B cells reveals possible pathogenesis involvement in pediatric immune thrombocytopenia. *Hematology.* 2019;24(1):473-479.

28. Giordano P, Cascioli S, Larsangro G, et al. B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy. *Pediatr Res.* 2016;79(2):262-270.

29. Pelanda R, Torres RM. Central B-cell tolerance: where selection begins. *Cold Spring Harb Perspect Biol.* 2012;4(4):a007146.

30. Li G, Wang S, Li N, et al. Proteasome inhibition with bortezomib induces apoptosis of long-lived plasma cells in steroid-resistant or relapsed immune thrombocytopenia. *Thromb Haemost.* 2018;118(10):1752-1764.

31. Shrestha S, Nabi I, Smith JW, Kelton JG, Arnold DM. Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia. *Blood Adv.* 2020;4(13):2962-2966.

32. Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. *Immunol Rev.* 2013;251(1):177-188.

33. Ochsenbein AF, Pinschewer DD, Sierro S, Horvath E, Hengartner H, Zinkernagel RM. Protective long-term antibody memory by antigen-driven and T cell-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. *Proc Natl Acad Sci USA.* 2000;97(24):13263-13268.

34. Fairfax KA, Kallies A, Nutt SL, Tarlinton DM. Plasma cell development: from B-cell subsets to long-term survival niches. *Cell Rep.* 2016;173(1):159-160.

35. Medvedovic J, Ebert A, Tagoh H, Busslinger M. Pax5: a master regulator of B cell development and leukemogenesis. *Adv Immunol.* 2011;111:179-206.

36. Low MSY, Brodie EJ, Fedele PL, et al. Irf4 activity is required in established plasma cells to regulate gene transcription and mitochondrial homeostasis. *Cell Rep.* 2019;29(9):2634-2645.e5.

37. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. *Nat Rev Immunol.* 2010;10(4):236-247.

38. Aslam R, Segel GB, Burack R, et al. Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells. *Br J Haematol.* 2016;173(1):159-160.

39. Aslam R, Hu Y, Gebremskesel S, et al. Thymic retention of CD4+CD25−Foxp3− T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. *Blood.* 2012;120(10):2127-2132.

40. Olsson B, Riedel B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. *Blood.* 2008;112(4):1078-1084.

41. Baba Y, Saito Y, Kotetsu Y. Heterogeneous subsets of B-lineage regulatory cells (Breg cells). *Int Immunol.* 2020;32(3):155-162.

42. Perera M, Garrido T. Advances in the pathobiology of primary immune thrombocytopenia. *Hematology.* 2017;22(1):41-53.

43. Chen W, Jin W, Hardegan N, et al. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med.* 2003;198(12):1875-1886.

44. Li H, Guan Y, Sun B, et al. Role of bone marrow-derived mesenchymal stem cell defects in CD8− CD28− suppressor T-lymphocyte induction in patients with immune thrombocytopenia and associated mechanisms. *Br J Haematol.* 2020;191(5):852-862.

45. Xu LL, Fu HX, Zhang JM, et al. Impaired function of bone marrow mesenchymal stem cells from immune thrombocytopenia patients in inducing regulatory dendritic cell differentiation through the notch-1/jagged-1 signaling pathway. *Stem Cells Dev.* 2017;26(22):1648-1661.

46. Guo Y, Chan KH, Lai WH, et al. Human mesenchymal stem cells upregulate CD1dCD5(+/-) regulatory B cells in experimental autoimmune encephalomyelitis. *Neuroimmunomodulation.* 2013;20(5):284-303.

47. Sáez de Guinoa J, Barrio L, Mellado M, Carrasco YR. CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. *Blood.* 2011;118(6):1560-1569.

48. Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. *Immunol Rev.* 2011;244(1):115-133.
49. Zhou Z, Chen Z, Li H, et al. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. *Autoimmunity.* 2009;42(2):112-119.

50. Zhu XJ, Shi Y, Zhang F, et al. Reduced tumour necrosis factor receptor superfamily 13C inversely correlated with tumour necrosis factor superfamily 13B in patients with immune thrombocytopenia. *Br J Haematol.* 2014;166(5):783-791.

51. Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. *Int Rev Immunol.* 2017;36(1):3-19.